menu
    • menu
    [{"orgOrder":0,"company":"Tiumbio","sponsor":"Oncodesign","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Nanocyclix Drug Candidates","moa":"kinase","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Tiumbio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"","sponsorNew":"Tiumbio \/ Oncodesign","highestDevelopmentStatusID":"4","companyTruncated":"Tiumbio \/ Oncodesign"},{"orgOrder":0,"company":"Tiumbio","sponsor":"Hansoh Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"HS-10518","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Tiumbio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Tiumbio \/ Hansoh Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Tiumbio \/ Hansoh Pharma"},{"orgOrder":0,"company":"Tiumbio","sponsor":"SK Chemicals","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Private Placement","leadProduct":"Merigolix","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Tiumbio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tiumbio \/ SK Chemicals","highestDevelopmentStatusID":"8","companyTruncated":"Tiumbio \/ SK Chemicals"},{"orgOrder":0,"company":"Tiumbio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"TU7710","moa":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Tiumbio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Tiumbio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tiumbio \/ Not Applicable"},{"orgOrder":0,"company":"Tiumbio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Merigolix","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Tiumbio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tiumbio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiumbio \/ Not Applicable"},{"orgOrder":0,"company":"Tiumbio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Tiumbio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Tiumbio \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Tiumbio \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Tiumbio

    Menu

    Tiumbio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Tiumbio

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed

                            Tiumbio

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TU2218,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            TiumBio Announces First Patient Dosed in Phase 2 Trial of TU2218

                            Details : TU2218 is a potentially first-in-class dual inhibitor targeting TGFR1 & VEGFR2, which is being evaluated for the treatment of solid tumors.

                            Brand Name : TU2218

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 04, 2024

                            Lead Product(s) : TU2218,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Tiumbio

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed

                            Tiumbio

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Merigolix

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            TiumBio Reports Positive Data from Phase 2a Trial of Merigolix for Endometriosis Pain

                            Details : TU2670 (merigolix) is a once-daily, oral gonadotropin-releasing hormone (GnRH) receptor antagonist, which is being investigated in females with endometriosis-associated-pain.

                            Brand Name : TU2670

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 08, 2024

                            Lead Product(s) : Merigolix

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Tiumbio

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed

                            Tiumbio

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TU7710

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            TiumBio Submits CTA for Phase 1b Trial of TU7710 in Hemophilia A or B Patients

                            Details : TU7710 is a recombinant activated factor VII for hemophilia A & B patients with inhibitors, in phase I clinical trials for blood coagulation disorders.

                            Brand Name : TU7710

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 26, 2024

                            Lead Product(s) : TU7710

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Tiumbio

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed

                            Tiumbio

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Merigolix

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase II

                            Sponsor : SK Chemicals

                            Deal Size : Undisclosed

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            TiumBio Secures KRW 38.5 Billion in Anticipation of Upcoming Clinical Data

                            Details : The proceeds will be primarily allocated to support TiumBio's clinical programs that include a Phase 2 trial of TU2670 (merigolix), a once-daily, oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in endometriosis.

                            Brand Name : TU2670

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 29, 2023

                            Lead Product(s) : Merigolix

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase II

                            Sponsor : SK Chemicals

                            Deal Size : Undisclosed

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Tiumbio

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed

                            Tiumbio

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HS-10518

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Hansoh Pharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            TiumBio and Hansoh Pharma Announce Clinical Trial Approval of 'HS-10518/TU2670' from NMPA in China

                            Details : TU2670 is an orally active non-peptide GnRH antagonist currently undergoing a Phase 2a clinical study in the EU for the treatment of moderate to severe pain associated with endometriosis.

                            Brand Name : TU2670

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 05, 2023

                            Lead Product(s) : HS-10518

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Hansoh Pharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Tiumbio

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed

                            Tiumbio

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nanocyclix Drug Candidates

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Preclinical

                            Sponsor : Oncodesign

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Oncodesign and TiumBio Sign Collaboration Agreement for R&D of Fibrosis Drug Candidates

                            Details : Under this agreement, Oncodesign will be responsible for identification, chemical synthesis and optimization of Nanocyclix drug candidates and their early-stage analysis, while TiumBio will be responsible for the advanced evaluation of fibrotic efficacy ...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 21, 2021

                            Lead Product(s) : Nanocyclix Drug Candidates

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Preclinical

                            Sponsor : Oncodesign

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth